Prometheus reportedly drew a competing AbbVie bid, initial partner interest from 16 pharmas before inking $10.8B Merck buyout

Andrew Dunn

Senior Biopharma Correspondent

In the week after this year’s JP Morgan Healthcare Conference, Prometheus Biosciences CEO Mark McKenna got a phone call that would change the biotech’s future …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Prometheus reportedly drew a competing AbbVie bid, initial partner interest from 16 pharmas before inking $10.8B Merck buyout

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

New fund will pressure flailing biotechs, as investor frustration boils over

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Prometheus re­port­ed­ly drew a com­pet­ing Ab­b­Vie bid, ini­tial part­ner in­ter­est from 16 phar­mas be­fore ink­ing $10.8B Mer­ck buy­out

Senior Biopharma Correspondent

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Prometheus reportedly drew a competing AbbVie bid, initial partner interest from 16 pharmas before inking $10.8B Merck buyout